New multisociety guidance identifies menstrual irregularities as potential early markers of cardiovascular risk, extending prevention efforts into adolescence.
Estrogen-based therapy is now recommended first for vasomotor symptoms, with SNRIs, SSRIs, gabapentin, and neurokinin receptor antagonists reserved for later lines.
Guideline recommends screening, diagnosis, positive airway pressure therapy, and postpartum reassessment while highlighting the very low certainty of available evidence.
A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.
Radiology groups say the ACP's new screening recommendations conflict with nearly every major cancer organization and could cost thousands of lives annually.